Protexeon Limited

Other

Leland Stanford Junior University

Imperial College of Science, Technology and Medicine

Air Products and Chemicals, Inc.

Mervyn Maze

Nicholas Peter Franks

Vladimir Nekhendzy

Juan Carlos Sacristan Martin

The present invention relates to the use of xenon in the preparation of a medicament for preventing and/or alleviating one or more anesthetic-induced neurological deficits in a neonatal subject. The present invention further relates to combinations of xenon and sevoflurane, and use thereof as preconditioning agents for administration prior to hypoxic-ischaemic injury.

Use of xenon as neuroprotectant in a neonatal subject

In a first aspect, the present invention relates to the use of xenon in the preparation of a medicament for providing analgesia in a newborn subject and/or a fetal subject. In a second aspect, the invention relates to a method of providing analgesia in a newborn subject, the method comprising administering to the subject a therapeutically effective amount of xenon. In a third aspect, the invention relates to a method of providing analgesia in a fetal subject, the method comprising administering to the mother of the fetal subject a therapeutically effective amount of xenon for both the mother and fetal subject.

Analgesic agent for newborn or fetal subjects

The present invention relates to methods of controlling neurological deficits in patients who have undergone cardiopulmonary bypass (CPB) by administering xenon to said patients.

Use of xenon for the control of neurological deficits associated with cardiopulmonary bypass

The present invention relates to the use of xenon in the preparation of a medicament for the treatment of neonatal asphyxia in a neonatal subject, wherein said medicament is for use in combination with hypothermia.

Use of xenon with hypothermia for treating neonatal asphyxia

The present invention relates to the use of xenon as a neuroprotectant and/or as an inhibitor of synaptic plasticity. In a preferred aspect, the xenon acts as an NMDA antagonist. The present invention also provides a method of reducing the level of activation of the NMDA receptors in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon, wherein said reduction achieves neuroprotection and/or an inhibition of synaptic plasticity. A further embodiment of the invention provides a pharmaceutical composition for providing neuroprotection and/or inhibition of synaptic plasticity, together with a process for the preparation thereof. Another aspect of the invention relates to a pharmaceutical composition suitable for providing neuroprotection, inhibiting synaptic plasticity or relieving neuropathic pain, said composition comprising xenon and a GABAergic agent admixed with a pharmaceutically acceptable carrier, excipient or diluent.

NMDA antagonist comprising xenon

A method of eliciting analgesia in a human subject by Transcranial Electrical Stimulation (TCES) is provided. Electrodes are secured to the skin of the subject's head and used to apply an electrical current to the electrodes. The current includes a direct current combined with rectangular current pulses (alternating current) delivered at a frequency of between 30 and 65 Hz. The frequency at which the pulses are delivered is periodically changed to a different value within the 30-65 Hz range. The total current supplied, a sum of the DC component and a Mean Absolute Deviation (MAD) of the current pulses, preferably has a value between 0.2 and 20 mA. The method is used during surgery and the post-operative procedure, and may also be used to treat a wide variety of neurological and other conditions.

Eliciting analgesia by transcranial electrical stimulation

A pharmaceutical composition is described. The composition comprises a formulation. The formulation comprises an NMDA antagonist and an alpha-2 adrenergic agonist. In a preferred aspect, there is provided an improved anaesthetic comprising an NMDA antagonist and an alpha-2 adrenergic agonist.

Anaesthetic formulation comprising an NMDA-antagoinst and an alpha-2 adrenergic agonist

The present invention relates to the use of xenon as an NMDA antagonist. In particular, the invention relates to a method of treatment comprising modulating the activity of an NMDA receptor in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon. In a further aspect, the invention provides a process for the preparation of a pharmaceutical composition suitable for modulating the activity of an NMDA receptor.

Growing community of inventors

London, United Kingdom

Mervyn Maze